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The retrovirus human T lymphotropic virus type 1 
(HTLV-1) causes a variety of human diseases with several 
clinical manifestations, including adult T cell lymphoma/
leukaemia (ATLL) (Poiesz et al. 1980) and HTLV-1-associ-
ated myelopathy/tropical spastic paraparesis (HAM/TSP) 
(Gessain et al. 1985). HTLV-1, like other retroviruses, uti-
lises the host cellular machinery to survive and propagate. 
Although the gene regulatory mechanisms involving host 
and viral proteins have been extensively studied, data on 
microRNAs (miRNAs) as mediators of gene regulation in 
viral infections are just emerging (Scaria et al. 2006).
The roles of human miRNAs in HTLV-1 infection 
are beginning to be elucidated; however, previous stud-
ies were performed on patients with only ATLL or on 
leukaemic cell lines (Yeung et al. 2008, Bellon et al. 
2009, Tomita et al. 2012), limiting the utility of these 
studies to one clinical manifestation characteristic of 
HTLV-1 infection and to cellular events characteristic of 
tumourigenesis, e.g., cellular proliferation and transfor-
mation. To understand whether transformation of the cell 
by HTLV-1 alters miRNA expression and to elucidate 
how miRNAs are deregulated during HTLV-1 infection, 
more studies examining HTLV-1 clinical manifestations 
are necessary. We conducted this study to address these 
questions. Our first aim was to quantify miRNA expres-
sion patterns that were altered in HTLV-1 asymptomatic 
carriers (HACs) and in patients with HAM/TSP. The 
second aim was to assess variations in miRNA expres-
sion and their associations with clinical conditions.
The control group (CT) in this study consisted of 21 
selected blood donors. The HTLV-1 group were classi-
fied into HAC subjects (n = 10) and HAM patients (n 
= 13), recruited from the Neurology Department of the 
Hospital of the University of São Paulo, Brazil. The study 
was approved by the Institutional Ethical Committee of 
the University Hospital, Faculty of Medicine of Ribeirão 
Preto, University of São Paulo (process 7639/2005). All 
subjects gave written informed consent to participate.
Proviral load (PL) was determined according to De-
hée et al. (2002). The standard used for HTLV-1 was DNA 
lysate from MT-2 cells (catalogue 93121518/ECACC, 
HPA Cultures, Salisbury, Wiltshire, UK), which con-
tains 2.4 copies per cell of the HTLV-1 provirus. The 
range of the PL in the MT2 standard was 105-101 copies 
per reaction. The PL values were normalised to the num-
ber of copies of the β-actin gene, of which two alleles 
per cell were present. The total sample copy number was 
estimated by interpolation from the standard curve as-
suming one proviral copy per cell.
Peripheral blood mononuclear cells (PBMCs) from 
all individuals were isolated from 40 mL of total periph-
eral blood using a Ficoll-PaqueTM density gradient (GE 
Healthcare, Uppsala, Uppsala län, Sweden). To quantify 
Tax protein by flow cytometry, at least 1 x 106 cells were 
cryopreserved in foetal calf serum (FCS) (HyClone, Lo-
gan, Utah, USA) with 10% dimethyl sulfoxide (Sigma-
Aldrich, Saint Louis, Missouri, USA). To isolate RNA 
from PBMCs, 1 x 107 cells were lysed in TRIzolTM (In-
vitrogen Life Technologies, Carlsbad, California, USA). 
From the TRIzolTM RNA preparation, the lower, phenol-
chloroform layer was saved and immediately after iso-
lating the RNA protein was extracted for western blot 
analysis (see below).
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The retrovirus human T lymphotropic virus type 1 (HTLV-1) promotes spastic paraparesis, adult T cell leukae-
mia and other diseases. Recently, some human microRNAs (miRNAs) have been described as important factors in 
host-virus interactions. This study compared miRNA expression in control individuals, asymptomatic HTLV-1 car-
riers and HTLV-1 associated myelopathy (HAM)/tropical spastic paraparesis patients. The proviral load and Tax 
protein expression were measured in order to characterize the patients. hsa-miR-125b expression was significantly 
higher in patients than in controls (p = 0.0285) or in the HAM group (p = 0.0312). Therefore, our findings suggest 
that miR-125b expression can be used to elucidate the mechanisms of viral replication and pathogenic processes.
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Cryopreserved cells were thawed, washed twice in 
phosphate buffered saline and then incubated for 12 h 
at 37ºC, 5% CO2 in
 complete medium consisting of RP-
MI-1640 medium (Sigma) supplemented with 10% FCS, 
2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin (Invitrogen Life Technologies) and 20 nM 
concanamycin (Sigma-Aldrich). After incubation, Tax 
protein was quantified in the cells as described by As-
quith et al. (2005).
Total proteins were isolated from the TRIzolTM su-
pernatant according to the manufacturer’s protocol and a 
total of 30 μg was used for western blot analysis. Briefly, 
the proteins were transferred to polyvinylidene fluoride 
membranes (GE HealthCare, Chalfont St Giles, Buck-
inghamshire, England) and nonspecific binding sites 
were blocked overnight in non-fat dry-milk at 4ºC. The 
membranes were incubated with monoclonal antibodies 
against Tax (Abcam, Cambridge, Massachusetts, USA) 
and tubulin (Santa Cruz Biotechnology, Santa Cruz, 
California, USA). Then, the membranes were washed 
with tris buffered saline-T solution and reincubated with 
peroxidase-conjugated secondary antibody (1:1.000; 
GE HealthCare, Chalfont St Giles, Buckinghamshire, 
England). The proteins were visualised using enhanced 
chemiluminescence (GE HealthCare, Chalfont St. Giles, 
Buckinghamshire, England).
Tax positivity in the PBMCs of HTLV-1-infected 
subjects, assessed by flow cytometry, was approximate-
ly 2.37%, which correlated with previous reports in the 
literature (Asquith et al. 2005). Due to the lack of flow 
cytometry samples from some subjects, distinct methods 
to measure Tax protein were used. To confirm if differ-
ent methods could provide similar data, we used Spear-
man’s test to determine the correlation of Tax protein 
expression in 11 samples. A significant p value of 0.0128 
was observed. Tax protein expression was analysed to 
correctly classify HTLV-1 patient groups (Table) and pa-
rameters were established to assess protein expression in 
the follow-up of HTLV-1 patients. 
The miRNAs chosen to have their expression changes 
in HTLV-1 patients were of the hsa-miR: 149a, 648, 221, 
222, 142-5p, 26a, 29a, 374 and 125b. All of these miR-
NAs were chosen because they are involved in important 
cellular pathways. For example, Ma et al. (2011) dem-
onstrated that miR-29 suppresses immune responses to 
intracellular pathogens by targeting interferon (IFN)-γ 
and Salvatori et al. (2011) showed that miR-26a inhibits 
cell cycle progression. In addition, miR-221 and miR-222 
are deregulated in a number of cancers and affect the ex-
pression of cell cycle regulatory proteins (Lambeth et al. 
2009). The expression of miR-142-5p is altered during T 
cell differentiation (Wu et al. 2007).
To analyse changes in miRNA expression, total 
RNA from patients and healthy controls were isolated 
from PBMCs by TRIzolTM. Then, the RNA was quanti-
fied and 2.5 ng of RNA from each sample was reverse-
transcribed (RT) using a High-Capacity cDNA Archive 
Kit (Applied Biosystems, Foster City, California, USA). 
Stem-loop RT primers specific for each miRNA were 
used in the RT-polymerase chain reaction (PCR) (Chen 
et al. 2005). Mature miRNAs were quantified using the 
TaqMan MicroRNA Assay (Applied Biosystems, Fos-
ter City, California, USA) according to the manufac-
turer’s protocol. Quantitative PCR was used to quantify 
the abundance of the RT-PCR products; results from 
all PBMC samples were normalised to the geometric 
mean result from three different small nucleolar RNAs 
(RNU 24, RNU48 and RNU43). Relative mRNA abun-
dance was quantified using the 2-∆∆Ct method. To assess 
expression of miRNAs, the Mann-Whitney U-test was 
used to compare patients vs. healthy donors. To compare 
control individuals vs. HAC and to compare control vs. 
HAM, the Kruskal-Wallis test was performed followed 
by Dunn’s post-test. The Spearman test was employed to 
evaluate the correlations between provirus copy number 
and microRNA expression. 
Of all miRNAs tested, miR-125b was the only 
miRNA that presented significant expression variation 
amongst the three groups. hsa-miR-125b expression was 
TABLE
Human T lymphotropic virus type 1 (HTLV-1) 
patients characterization
Sample Gender
Age 
(years)
Proviral 
load
Tax protein
Western
Flow 
cytometry
HAC 01 F 52 50.96 0.80 ND
HAC12 F 51 491.94 1.36 ND
HAC13 F 42 ND 2.01 ND
HAC15 M 53 ND 1.11 ND
HAC16 F 55 ND 0.40 0.87
HAC19 F 33 233.88 0.21 0.48
HAC20 M 45 224.96 1.94 ND
HAC21 M 46 ND 0.61 4.12
HAC22 M 61 0.00 0.52 ND
HAC23 F 46 0.00 0.08 0.53
HAM01 F 55 368.18 1.00 1.20
HAM02 F 34 1.233.97 2.76 ND
HAM05 F 61 3.296.98 0.81 3.39
HAM08 M 47 1.090.20 0.97 ND
HAM09 M 64 775.40 0.64 4.56
HAM13 F 49 303.78 1.16 ND
HAM14 F 61 ND 0.67 4.21
HAM15 F 62 1.323.84 ND ND
HAM16 M 54 0.00 0.14 1.15
HAM17 F 55 42.07 0.24 1.09
HAM18 F 48 ND 0.58 2.75
HAM19 F 42 2.068.97 1.09 ND
the analyses (western vs. flow cytometry) were evaluated by 
Spearman’s test (p = 0.0128). The correlation was applied due 
to the lack of cells to be evaluated by flow cytometry (the pref-
erential method). HAC: HTLV-1 asymptomatic carrier; HAM: 
HTLV-1 associated myelopathy/tropical spastic paraparesis; 
ND: not determined.
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significantly higher in patients than controls (p = 0.0285) 
(A in Figure). When the groups were re-analysed after 
classifying by clinical condition (Tax protein level), hsa-
miR-125b presented a progressive increase in expression 
from CT to HAC to HAM (p = 0.0312) (B in Figure). Our 
findings show that hsa-miR-125b expression increased in 
HTLV-1 carriers and HAM patients; however, the Spear-
man correlations of hsa-miR-125b expression with PL 
and Tax expression did not suggest any statistical sig-
nificance (data not shown). It is possible that host factors, 
which can be involved in miR-125b deregulation, contrib-
uted to the absence of statistically significant correlations 
between miR-125b expression and HTLV-1 infection. 
The viral protein Tax is capable of inactivating p53 
and compromising several cellular events (Taylor & 
Nicot 2008). Recently Le et al. (2011) demonstrated that 
miR-125b is responsible for regulating 20 novel targets 
in the p53 pathway. Therefore, it is reasonable to believe 
that some deregulation of miRNA expression could 
be correlated with p53 inactivation. Rossi et al. (2011) 
demonstrated that during the transformation of naïve 
TCD4+ to effector memory cells, miR-125b expression 
significantly decreases. When this miRNA is added ex-
ogenously into TCD4+ cells, they secrete less IFN-γ and 
express interleukin-2Rβ, suggesting that high expression 
of miR-125b inhibits the secretion of IFN-γ by TCD4+ 
effector cells. Additionally, Rajaram et al. (2011) dem-
onstrated that miR-125b is responsible for reducing the 
production of TNF-α in infected macrophages when the 
macrophages are activated to produce TNF-α in a model 
of tuberculosis.
In patients with HTLV-1, especially patients with 
an enhanced inflammatory response, both TNF-α and 
IFN-γ secretion are increased (Yamana et al. 2009). 
While further studies will be crucial to elucidate if miR-
125b is increased in virus carriers, miR-125b expression 
should be assessed in HAM/TSP patients, as an increase 
in expression may result from a host’s attempt to control 
the production of TNF-α and IFN-γ. Experiments cor-
relating miR-125b expression with TNF-α, IFN-γ and/
or p53 levels may also be important for elucidating the 
mechanism by which certain patient populations develop 
myelopathy. Furthermore, assessing miR-125b expres-
sion in patients over a time course, for example, in the 
follow-up of HAC patients, could determine if the level 
of miR-125b can be used as a diagnostic marker. 
In conclusion, we suggest that further studies 
analysing the miRNAs that exhibit altered expression 
patterns in HAM/TSP will likely enhance our under-
standing of how miRNAs participate in the progression 
of myelopathy and will open avenues for new therapeu-
tic approaches.
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